Promising topline results from a phase 3B study show the efficacy and quality of life (QOL) improvements of iptacopan ...

The Max Foundation expands collaboration with Novartis to include access to innovative treatment for paroxysmal nocturnal hemoglobinuria: Seattle, Washington Monday, December 9, 2 ...

At this year’s ASH conference, Regeneron posted results for treatments that could disrupt the standards of care in two blood-related diseases.

These treat conditions like hypertrophic cardiomyopathy, and intractable epilepsy. China’s National Healthcare Security ...

Omeros Corporation (Nasdaq: OMER) today announced that two posters directed to zaltenibart (OMS906), Omeros’ investigational ...

NVS' Fabhalta improves the average hemoglobin level compared to baseline in adult patients with PNH who switched from anti-C5 ...

The single-arm, open-label APPULSE-PNH trial included 52 PNH patients who were on a stable regimen with either eculizumab or ravulizumab.

Regeneron Pharmaceuticals Inc. (REGN) announced positive updated Phase 3 data of an exploratory cohort from the ACCESS-1 trial ...

Novartis (NVS) announced positive topline results from APPULSE-PNH, a Phase IIIB study evaluating the efficacy and safety of twice-daily oral ...

Pharmaceuticals announced updated Phase 3 data of an exploratory cohort from the ACCESS-1 trial investigating its ...

A total of 13 rare-disease drugs have been added to the latest edition of China medical insurance drug catalog bringing the total amount of such medi ...